SCHEMBL3768285

SCHEMBL3768285

O=C(CN1CCN(c2ccc(F)c(C(F)(F)F)c2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
GFER P55789 1/20 0.46
ALDH1A1 P00352 5/20 0.44
MAPT P10636 4/20 0.44
HRH3 Q9Y5N1 2/20 0.44
NPC1 O15118 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.42
AR P10275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766241 0.98 NOTUM (0.47) NOTUMMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL3767483 0.97 NOTUM (0.47) NOTUMMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL3765450 0.89 NOTUM (0.50) NOTUMMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL5550621 0.87 NPSR1 (0.45) MEN1KMT2ATSHRSMN1; SMN2GFER
SCHEMBL3773971 0.87 NOTUM (0.50) NOTUMMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL3773770 0.86 NOTUM (0.49) NOTUMMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL3773835 0.84 ME2 (0.55) MEN1KMT2ASMN1; SMN2GFERALDH1A1
SCHEMBL3770102 0.82 MAPT (0.59) MEN1KMT2ASMN1; SMN2GFERALDH1A1
SCHEMBL3772005 0.82 GFER (0.50) MEN1KMT2ATSHRSMN1; SMN2GFER
SCHEMBL3762865 0.82 POLB (0.61) MEN1KMT2ASMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 NOTUM 2023/4885MEN1 3270/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.